Dr Reddy's Laboratories on Thursday said commercial supplies of its semaglutide product will be delayed after certain batches were found to be out of specification due to an issue with the active pharmaceutical ingredient (API) used in the drug.
In an exchange filing, the Hyderabad-based drugmaker said it is investigating the root cause of the issue and taking appropriate measures to ensure product quality.
